Gilead Pricing Strategy For Hepatitis C Drug Sovaldi Focused on Maximizing Profits Not Patients: Report A U.S. Senate probe showed that Gilead Sciences planned to maximize profits for its hepatitis C drugs, with affordability and patient access as a mere “afterthought.” The investigation centered on the costs of Sovaldi and combination drug Harvoni. by Katrina Pascual
Healthy Living/Wellness FDA Embroiled In Legal Battle Over Gilead Hepatitis C Drug Trial by Jill Arce
Healthy Living/Wellness FDA approves Gilead's Harvoni drug: Can we afford the $1125 once-a-day Hepatitis C pill? by Aaron Mamiit